Study #2024-0053
Cemiplimab and Cetuximab prior salvage surgery in patients with recurrent oral cavity squamous cell carcinoma (OCSCC).
MD Anderson Study Status
Enrolling
Treatment Agent
Cemiplimab, Cetuximab
Description
To learn if giving cemiplimab and cetuximab before salvage surgery can help to control recurrent oral cavity squamous cell carcinoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Locally Recurrent Oral Cavity Squamous Cell Carcinoma
Study phase:
Phase II
Physician name:
Luana Guimaraes De Sousa
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-404-4637
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.